Singapore markets closed

LLY Jan 2025 360.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
0.96000.0000 (0.00%)
At close: 12:27PM EDT
Full screen
Loading interactive chart…
  • Yahoo Finance Video

    Ether ETF approved, Live Nation antitrust suit: Morning Brief

    After an eventful week compounded by Nvidia's (NVDA) fiscal first-quarter earnings, the major market averages (^DJI, ^IXIC, ^GSPC) are hoping to end the week on a high note and claw back some gains ahead of the Memorial Day Weekend. Morning Brief Hosts Seana Smith and Brad Smith walk investors through the top stories moving stocks in Friday's trading day, kicking off the session with Truist Co-Chief Investment Officer and Chief Market Strategist Keith Lerner who compares the market sway of Nvidia's latest earnings to that of inflation data or the Federal Reserve's monetary policy. The Securities and Exchange Commission (SEC) approved ether ETF offerings on Thursday, leading Bloomberg Intelligence ETF Research Analyst James Seyffart to believe ethereum-exposed (ETH-USD) products will have similar success to the spot bitcoin ETFs (BTC-USD) rolled out at the start of 2024, just not on the same scale. Other top trending stories include the latest in the Department of Justice's (DOJ) antitrust suit against concert promoter and ticket seller Live Nation (LYV) and Charter Communications' (CHTR) content distribution deal with Paramount Global (PARA). This post was written by Luke Carberry Mogan.

  • Benzinga

    Eli Lilly Makes Largest Manufacturing Investment In Its History To Boost Production For Antidiabetic And Weight Loss Meds

    Friday, Eli Lilly And Company (NYSE:LLY) announced it has more than doubled its investment in its Lebanon, Indiana, manufacturing site with a new $5.3 billion commitment, increasing its total investment from $3.7 billion to $9 billion. This expansion will enhance Lilly’s capacity to manufacture active pharmaceutical ingredients (API) for Zepbound (tirzepatide) injection and Mounjaro (tirzepatide) injection. Related: Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires M

  • Associated Press Finance

    Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro

    Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The company broke ground for its Lebanon, Indiana, manufacturing plant last year and expects to start making products there near the end of 2026. Lilly said it would add $5.3 billion to the $3.7 billion it had already slated for the site.